Equillium (EQ) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Equillium (NYSE:EQ) in a report issued on Tuesday, The Fly reports. The firm issued a buy rating and a $22.00 target price on the stock.

Equillium stock traded down $0.05 during mid-day trading on Tuesday, hitting $16.94. The company’s stock had a trading volume of 3,271 shares, compared to its average volume of 37,089. Equillium has a twelve month low of $9.21 and a twelve month high of $19.27.

Equillium Company Profile

Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma.

Recommended Story: Dividend Aristocrat Index

The Fly

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply